Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-15
2011-03-15
Bertoglio, Valarie (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S325000
Reexamination Certificate
active
07906637
ABSTRACT:
Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.
REFERENCES:
patent: 2003/0096773 (2003-05-01), Crooke et al.
Broomfield and Kirby, Journal of Applied Toxicology, 2001, 21:S53-S46.
NCBI Accession No. AF036930 [gi:3219694] with Revision History, Jun. 15, 1998-Jun. 20, 1998.
NCBI Accession No. M73499 [gi:179927] with Revision History, Oct. 31, 1991-Apr. 27, 1993.
Bencharit et al., “Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug Tacrine:from binding promiscuity to selective inhibition”, Chemistry & Biology 2003 10:341-349.
Bencharit et al., “Structural insights into CPT-11 activation by mammalian carboxylesterases”, Nature Structural Biology 2002 9(5):337-342.
Danks et al., “Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy”, Clinical Cancer Research 1999 5:917-924.
Meck et al., “A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carbosylesterase and CPT-11”, Cancer Research 2001 61:5083-5089.
Potter et al., “Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11)”, Cancer Research 1998 58:2646-2651.
Humerickhouse et al., “Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2”, Cancer Research 2000 60:1189-1192.
Khanna et al., “Proficient metabolism of irinotecan by a human intestinal carboxylesterase”, Cancer Research 2000 60:4725-4728.
Redinbo et al., “Human carboxylesterase 1:from drug metabolism to drug discovery”, Biochemical Society Transactions 2003 31(3):620-624.
Rooseboom et al., “Enzyme-catalyzed activation of anticancer prodrugs”, Pharmacological Reviews 2004 56(1):53-102.
Wadkins et al., “Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases”, Molecular Pharmacology 2001 60:355-362.
Wagner et al., “Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method:preclinical assessment and application to bone marrow samples from neuroblastoma patients”, Cancer Research 2002 62:5001-5007.
Wierdl et al., “Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase”, Cancer Research 2001 61:5078-5082.
Potter Philip M.
Redinbo Matthew R.
Weirdl Monika
Bertoglio Valarie
Licata & Tyrrell P.C.
St. Jude Children's Research Hospital
The University of North Carolina at Chapel Hill
LandOfFree
Compositions and methods for inducing or inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inducing or inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inducing or inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706772